Ascendis Pharma AS (STU:A710) Cyclically Adjusted PS Ratio: (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:A710 Ascendis Pharma AS STU:A710
46 GF Score
Price €232.00
! 3 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS  (STU:A710) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ascendis Pharma AS Cyclically Adjusted PS Ratio Related Terms


Ascendis Pharma AS Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted PS Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascendis Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 69.81

STU:A710 vs JAZZ, BBIO, EXEL: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PS Ratio falls into.


STU:A710
46GF Score
Ascendis Pharma AS STU:A710
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ascendis Pharma AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.966/122.9700*122.9700
=4.966

Current CPI (Jun. 2026) = 122.9700.

Ascendis Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.046 100.200 0.056
201612 0.034 100.300 0.042
201703 0.011 101.200 0.013
201706 0.014 101.200 0.017
201709 0.013 101.800 0.016
201712 0.008 101.300 0.010
201803 0.001 101.700 0.001
201806 0.000 102.300 0.000
201809 0.000 102.400 0.000
201812 0.250 102.100 0.301
201903 0.125 102.900 0.149
201906 0.068 102.900 0.081
201909 0.047 102.900 0.056
201912 0.052 102.900 0.062
202003 0.046 103.300 0.055
202006 0.030 103.200 0.036
202009 0.052 103.500 0.062
202012 0.010 103.400 0.012
202103 0.014 104.300 0.017
202106 0.019 105.000 0.022
202109 0.020 105.800 0.023
202112 0.086 106.600 0.099
202203 0.120 109.900 0.134
202206 0.110 113.600 0.119
202209 0.274 116.400 0.289
202212 0.409 115.900 0.434
202303 0.599 117.300 0.628
202306 0.843 116.400 0.891
202309 0.854 117.400 0.895
202312 2.186 116.700 2.303
202403 1.686 118.400 1.751
202406 0.592 118.500 0.614
202409 1.005 118.900 1.039
202412 2.908 118.900 3.008
202503 1.682 120.200 1.721
202506 2.473 120.700 2.520
202509 3.516 121.600 3.556
202512 4.045 121.200 4.104
202603 3.822 121.680 3.863
202606 4.966 122.970 4.966

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS Business Description

Other Exchanges ASND:USAA1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
46GF Score

Get the complete analysis for STU:A710

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€232.00
Price